CC
NPCE icon

Corton Capital’s Neuropace NPCE Stock Holding History

Corton Capital’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$119K Sell
11,586
-12,755
-52% -$120K 0.29% 162
2025
Q2 		$271K Buy
24,341
+7,817
+47% +$97.7K 0.32% 106
2025
Q1 		$203K Buy
+16,524
New +$207K 0.67% 61

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Corton Capital's NPCE Position: Q3 2025 in Review

Corton Capital reduced its Neuropace (NPCE) stake by 52% in Q3 2025, selling an estimated $120K and leaving 11,586 shares worth $119K. The position accounts for 0.29% of the portfolio, ranked #162.

Corton Capital first reported a position in NPCE in Q1 2025 and has held it in 3 quarters since. The position peaked at $271K in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Corton Capital held 11,586 shares of Neuropace worth $119K as of Q3 2025.
  • Corton Capital sold 12,755 Neuropace shares in Q3 2025, an estimated $120K.
  • Neuropace made up 0.29% of Corton Capital's portfolio in Q3 2025, its #162 holding.
  • Corton Capital first reported a position in Neuropace in Q1 2025 and has held it in 3 quarters since.
  • Corton Capital's Neuropace position peaked at $271K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Corton Capital's 13F filing for Q3 2025, filed 14 Nov 2025.